

# Sebastien Lacroix-Desmazes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/299353/sebastien-lacroix-desmazes-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

2,484  
citations

24  
h-index

49  
g-index

74  
ext. papers

2,831  
ext. citations

8.5  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
72	Inhibitors-Recent insights. <i>Haemophilia</i> , <b>2021</b> , 27 Suppl 3, 28-36	3.3	5
71	IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. <i>Nature Medicine</i> , <b>2020</b> , 26, 1096-1101	50.5	77
70	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 810	8.4	5
69	Noncanonical Functions of Antibodies. <i>Trends in Immunology</i> , <b>2020</b> , 41, 379-393	14.4	8
68	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. <i>Haematologica</i> , <b>2020</b> , 105, 1129-1137	6.6	7
67	A molecular jewel for hemophilia A treatment. <i>Blood</i> , <b>2020</b> , 135, 1417-1419	2.2	
66	Emergence of antibodies endowed with proteolytic activity against High-mobility group box 1 protein (HMGB1) in patients surviving septic shock. <i>Cellular Immunology</i> , <b>2020</b> , 347, 104020	4.4	1
65	Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. <i>Haemophilia</i> , <b>2020</b> , 26, 958-965	3.3	5
64	Removal of Mannose-Ending Glycan at Asn Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 393	8.4	0
63	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218258	3.7	9
62	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. <i>Haematologica</i> , <b>2019</b> , 104, e369-e372	6.6	4
61	Tolerating Factor VIII: Recent Progress. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2991	8.4	19
60	Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A. <i>Haematologica</i> , <b>2019</b> , 104, 1046-1054	6.6	3
59	Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. <i>Haematologica</i> , <b>2019</b> , 104, 236-244	6.6	17
58	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. <i>Cellular Immunology</i> , <b>2018</b> , 325, 64-68	4.4	3
57	Absence of a neutralizing antibody response to humanized cobra venom factor in mice. <i>Molecular Immunology</i> , <b>2018</b> , 97, 1-7	4.3	6
56	Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 517-530	5.3	8

55	Catalytic antibodies in patients with systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , <b>2018</b> , 5, 173-178	1.7	2
54	Complement C3 is a novel modulator of the anti-factor VIII immune response. <i>Haematologica</i> , <b>2018</b> , 103, 351-360	6.6	13
53	Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors. <i>Cellular Immunology</i> , <b>2018</b> , 331, 22-29	4.4	3
52	The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. <i>Haematologica</i> , <b>2017</b> , 102, 271-281	6.6	18
51	CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. <i>Blood Advances</i> , <b>2017</b> , 1, 1842-1847	7.8	16
50	Immunogenicity of long-lasting recombinant factor VIII products. <i>Cellular Immunology</i> , <b>2016</b> , 301, 40-8	4.4	30
49	Key insights to understand the immunogenicity of FVIII products. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116 Suppl 1, S2-9	7	7
48	Monoepitopic anti-FVIII T-cell response. <i>Blood</i> , <b>2016</b> , 128, 1999-2001	2.2	1
47	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4075-81	5.3	2
46	Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 275ra21	17.5	33
45	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 3532-42	0.9	19
44	Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. <i>Haematologica</i> , <b>2015</b> , 100, 149-56	6.6	30
43	A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 17767-79	5.4	14
42	Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. <i>Journal of Immunological Methods</i> , <b>2014</b> , 407, 26-34	2.5	13
41	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. <i>Blood</i> , <b>2014</b> , 123, 121-5	2.2	54
40	Antibody polyreactivity in health and disease: statu variabilis. <i>Journal of Immunology</i> , <b>2013</b> , 191, 993-9	5.3	74
39	Antibody-mediated catalysis: induction and therapeutic relevance. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 648-56	5.26	17
38	IVIg treatment reduces catalytic antibody titers of renal transplanted patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e70731	3.17	3

37	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. <i>Haematologica</i> , <b>2013</b> , 98, 1650-5	6.6	22
36	A novel molecular analysis of genes encoding catalytic antibodies. <i>Molecular Immunology</i> , <b>2012</b> , 50, 160-8	4.3	11
35	Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. <i>Biochemistry</i> , <b>2012</b> , 51, 4108-16	3.2	17
34	Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 1172-3; author reply 1174-5	11.5	9
33	Autoantibodies with enzymatic properties in human autoimmune diseases. <i>Journal of Autoimmunity</i> , <b>2011</b> , 37, 144-50	15.5	25
32	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. <i>Blood</i> , <b>2011</b> , 117, 2257-64	2.2	33
31	"Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002095	7.6	12
30	Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice. <i>Immunology</i> , <b>2010</b> , 131, 549-55	7.8	2
29	Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 1093-8	7	8
28	Heterogeneous antigen recognition behavior of induced polyspecific antibodies. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 398, 266-71	3.4	24
27	Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. <i>Blood</i> , <b>2010</b> , 115, 2682-5	2.2	25
26	Inhibitors of factor VIII in hemophilia. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 308; author reply 310	59.2	3
25	Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. <i>FEBS Letters</i> , <b>2009</b> , 583, 2565-72	3.8	18
24	Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2009</b> , 37, 97-104	12.3	2
23	A cellular viewpoint of anti-FVIII immune response in hemophilia A. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2009</b> , 37, 105-13	12.3	17
22	Functional variability of antibodies upon oxidative processes. <i>Autoimmunity Reviews</i> , <b>2008</b> , 7, 574-8	13.6	17
21	The role of VWF in the immunogenicity of FVIII. <i>Thrombosis Research</i> , <b>2008</b> , 122 Suppl 2, S3-6	8.2	13
20	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. <i>Haematologica</i> , <b>2008</b> , 93, 83-9	6.6	32

19	Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. <i>Journal of Immunology</i> , <b>2008</b> , 181, 1609-15	5.3	14
18	Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. <i>Journal of Immunology</i> , <b>2008</b> , 180, 7714-20	5.3	40
17	Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. <i>Journal of Immunology</i> , <b>2008</b> , 180, 8455-60	5.3	21
16	Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. <i>Blood</i> , <b>2008</b> , 111, 715-22	2.2	226
15	Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. <i>Blood</i> , <b>2008</b> , 112, 240-9	2.2	68
14	Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. <i>Haematologica</i> , <b>2007</b> , 92, 1423-6	6.6	35
13	Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. <i>Expert Review of Clinical Immunology</i> , <b>2007</b> , 3, 677-81	5.1	5
12	Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. <i>Nature Clinical Practice Rheumatology</i> , <b>2007</b> , 3, 262-72		84
11	VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. <i>Blood</i> , <b>2007</b> , 109, 610-2	2.2	158
10	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 8965-70	11.5	98
9	Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 439-46	5.4	56
8	Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1355-63	5.3	43
7	Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. <i>Blood Coagulation and Fibrinolysis</i> , <b>2006</b> , 17, 229-34	1	2
6	High levels of catalytic antibodies correlate with favorable outcome in sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 4109-13	11.5	104
5	Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. <i>Journal of Immunology</i> , <b>2004</b> , 172, 4676-80	5.3	381
4	Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. <i>Blood Coagulation and Fibrinolysis</i> , <b>2004</b> , 15, 109-24	1	65
3	Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 813-22	7	14
2	The prevalence of proteolytic antibodies against factor VIII in hemophilia A. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 662-7	59.2	94

1 Catalytic activity of antibodies against factor VIII in patients with hemophilia A. *Nature Medicine*,  
**1999**, 5, 1044-7

50.5 160